Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1
Paula Poikonen‐Saksela(Turku University Hospital), Johan Ahlgren(Uppsala University), Troels Bechmann(Hospital South West Jutland), Bent Ejlertsen, Søren Cold(Aarhus University Hospital), Per Edlund(Gävle Hospital), Ásgerður Sverrisdóttir(Uppsala University Hospital), Carl Blomqvist(University of Helsinki), Henrik Lindman(Uppsala University), Jonas Bergh(Karolinska Institutet), Michael Andersson(University of Copenhagen), Lars Stenbygaard(Aarhus University Hospital), Kenneth Villman(Örebro University Hospital), Lena Tennvall Nittby(Skåne University Hospital)
Cited by 5
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Association analysis identifies 65 new breast cancer risk loci
|Nature|2017|1.6k